Telix’s next-generation PSMA-PET imaging agent for prostate cancer, Gozellix receives US FDA approves: Melbourne, Australia Monday, March 24, 2025, 17:00 Hrs [IST] Telix, a biop ...
Key Takeaways Telix Pharmaceuticals reported that the U.S. Food and Drug Administration approved its agent indicated for ...
The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 ...
The PSMA-PET imaging agent will be used for patients who have suspected metastasis and those with suspected cancer recurrence.
(RTTNews) - Telix Pharmaceuticals (TLX) announced the FDA has approved its New Drug Application for Gozellix, next-generation PSMA-PET imaging agent for prostate cancer. Gozellix, after ...
The ASX 200 healthcare stock received another FDA approval for its cancer detection product. The post Up 113% in a year, ...
TLX007-CDx was approved by the FDA for PSMA-PET scanning in adult male patients with prostate cancer with suspected ...
Telix Pharmaceuticals' said its new drug application in the U.S. for an imaging agent received regulatory approval. The Melbrourne, Australia-based biopharmaceutical company said Friday that the Food ...
Stockhead on MSN15h
Health Check: Opthea’s solvency in question after monumental phase III eye disease trial failureOne of two of Opthea's phase III trials for a common eye disease has failed to meet its objectives, casting doubts on the ...
Vietnam Investment Review on MSN3d
FDA Approves New Prostate Cancer Imaging Agent Gozellix®Telix Pharmaceuticals Limited today announces that the United States Food and Drug Administration has approved its New Drug ...
Gozellix® builds on the success of Telix’s established PSMA-PET imaging agent, Illuccix®, and will be available alongside the first-generation product, providing choice for customers and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback